150 likes | 256 Views
Negative Trials. TRILOGY ACS No significant difference in ischemic outcomes despite greater P2Y 12 receptor inhibition with prasugrel than with clopidogrel. ISIS-2, GUSTO: Exclusion Criteria. Today’s Trial Design Challenges. NIH Health Care Systems Research Collaboratory.
E N D
TRILOGY ACSNo significant difference in ischemic outcomes despite greater P2Y12 receptor inhibition with prasugrel than with clopidogrel